Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children

Akindeh M Nji, Innocent M Ali, Marcel N Moyeh, Eric-Oliver Ngongang, Aristide M Ekollo, Jean-Paul Chedjou, Valentine N Ndikum, Marie S Evehe, Guenter Froeschl, Christian Heumann, Ulrich Mansmann, Olumide Ogundahunsi, Wilfred F Mbacham, Akindeh M Nji, Innocent M Ali, Marcel N Moyeh, Eric-Oliver Ngongang, Aristide M Ekollo, Jean-Paul Chedjou, Valentine N Ndikum, Marie S Evehe, Guenter Froeschl, Christian Heumann, Ulrich Mansmann, Olumide Ogundahunsi, Wilfred F Mbacham

Abstract

Background: Artemether-lumefantrine and artesunate-amodiaquine are first-line treatment for uncomplicated malaria in Cameroon. No study has yet compared the efficacy of these drugs following the WHO recommended 42-day follow-up period. The goal of this study was to compare the clinical efficacy, tolerability and safety of artesunate-amodiaquine (ASAQ), artemether-lumefantrine (AL) and dihydroartemisinin piperaquine (DHAP) among children aged less than ten years in two malaria-endemic ecological regions of Cameroon.

Methods: A three-arm, randomized, controlled, non-inferiority trial was conducted among children of either gender aged six months (>5 kg) to ten years (n = 720) with acute uncomplicated Plasmodium falciparum infection. Parents/guardians of children provided consent prior to randomization to receive ASAQ, DHAP or AL in the ratio of 2:2:1, respectively. Treatment outcome was assessed based on standard WHO 2003 classification after 42 days of follow-up. The primary outcome was PCR-corrected day-42 cure rates. The non-inferiority, one-sided, lower limit asymptotic 97.5% confidence interval (CI) on the difference in PCR-corrected cure rates of ASAQ and DHAP when compared to AL was accepted if the lower limit of the CI was greater than -10%. Secondary outcomes were parasite and fever clearances and day 7 haemoglobin changes.

Results: PCR-corrected PP cure rates of 96.7, 98.1 and 96.3, respectively, for AL, ASAQ and DHAP was observed. The lower bound of the one-sided 97.5% CI calculated around the difference between day-42 cure rate point estimates in AL and ASAQ groups, AL and DHAP groups were, -6% and -4% respectively. There were no statistical significant differences in parasite or fever clearance times between treatments, although fever clearance pattern was different between ASAQ and DHAP. No statistical significant differences were observed in the occurrence of adverse events among treatment groups.

Conclusion: ASAQ and DHAP are considered safe and tolerable and are not inferior to AL in the treatment of uncomplicated P. falciparum malaria in Cameroonian children.

Trial registration: NCT01845701.

Figures

Figure 1
Figure 1
The trial profile.
Figure 2
Figure 2
Parasite and fever clearing patterns.

References

    1. WHO . World Malaria report 2011. Geneva: World Health Organization; 2011.
    1. MOH . Ministère de la Santé Publique: plan stratégique national de lutte contre le paludisme 2011–2015. Cameroon: Ministry of Public Health; 2012.
    1. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol. 2009;7:864–74.
    1. Basco LK, Ndounga M, Same-Ekobo A, Yomba JC, Abodo RT, Soula G. Molecular epidemiology of malaria in Cameroon. XXI. Baseline therapeutic efficacy of chloroquine, amodiaquine, and sulfadoxine-pyrimethamine monotherapies in children before national drug policy change. Am J Trop Med Hyg. 2006;75:388–95.
    1. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al. Averting a malaria disaster. Lancet. 1999;353:1965–7. doi: 10.1016/S0140-6736(98)07367-X.
    1. NMCP-Cameroon . Cameroon national malaria control programme Report. Cameroon: Ministry of Public Health; 2006.
    1. WHO . Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria. Geneva: World Health Organization; 2003.
    1. Whegang SY, Tahar R, Foumane VN, Soula G, Gwet H, Thalabard JC, et al. Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon. Malar J. 2010;9:1–10. doi: 10.1186/1475-2875-9-1.
    1. Smith DL, Klein EY, McKenzie FE, Laxminarayan R. Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty. Malar J. 2010;9:56. doi: 10.1186/1475-2875-9-56.
    1. da Silva GT, Klein JP. Methods for equivalence and noninferiority testing. Biol Blood Marrow Transplant. 2008;15:120–7. doi: 10.1016/j.bbmt.2008.10.004.
    1. Create a randomisation list: []
    1. Plowe CV, Bouare M, Doumbo OK, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg. 1995;52:565–8.
    1. Nambozi M, Van Geertruyden J-P, Hachizovu S, Chaponda M, Mukwamataba D, Mulenga M, et al. Safety and efficacy of dihydroartemisinin- piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar J. 2011;10:50. doi: 10.1186/1475-2875-10-50.
    1. Kabanywanyi AM, Mwita A, Sumari D, Mandike R, Mugittu K, Abdulla S. Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania. Malar J. 2007;6:146. doi: 10.1186/1475-2875-6-146.
    1. The Four Artemisinin-Based Combinations (4ABC) Study Group A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011;8:1–16.
    1. Adjei GO, Kurtzhals JA, Rodrigues OP, Alifrangis M, Hoegberg LC, Kitcher ED, et al. Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J. 2008;7:127. doi: 10.1186/1475-2875-7-127.
    1. Meremikwu M, Ejemot E, Oyo-Ita A, Ekenjoku J, Nwachukwu C, Ordu D, et al. Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial. Malar J. 2006;5:43. doi: 10.1186/1475-2875-5-43.
    1. NMCP-Cameroon . National Malaria Control Program report, 2012. Cameroon: Ministry of Public Health; 2012.
    1. WHO/UNICEF . The Africa Malaria Report 2003. Geneva: World Health Organization; 2003.
    1. Mangham LJ, Cundill B, Achonduh OA, Ambebila JN, Lele AK, Metoh TN, et al. Malaria prevalence and treatment of febrile patients at health facilities and medicine retailers in Cameroon. Trop Med Int Health. 2012;17:330–42.
    1. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67. doi: 10.1056/NEJMoa0808859.
    1. Lokki AL, Järvelä I, Israelsson E, Maiga B, Troye-Blomberg M, Dolo D, et al. Lactase persistence genotypes and malaria susceptibility in Fulani of Mali. Malar J. 2011;10:9. doi: 10.1186/1475-2875-10-9.
    1. Modiano D, Sirima BS, Nebié I, Diallo D, Esposito F, Coluzzi M. Different response to Plasmodium falciparum malaria in west African sympatric ethnic groups. Proc Natl Acad Sci U S A. 1996;93:13206–11. doi: 10.1073/pnas.93.23.13206.
    1. Anderson B, Vullo C. Did malaria select for primary adult lactase deficiency? Gut. 1994;35:1487–9. doi: 10.1136/gut.35.10.1487.
    1. Zani B, Donegan S, Olliaro PL, Sinclair D. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014;1

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner